Zoetis Diagnostics Expansion Gains Momentum After Q2 Results and VitalRADS Integration

Zoetis (NYSE: ZTS) is reinforcing its position in diagnostic services through the recent closing of the VitalRADS acquisition, following its second-quarter earnings release that highlighted growing diagnostics momentum.

Diagnostics Gain Spotlight in Q2

In its second-quarter 2026 earnings report, released on August 6, Zoetis reported a steady revenue of $2.5 billion, with adjusted net income of $781 million (or $1.87 per diluted share). While U.S. growth was pressured across companion animal products, the international segment benefited from an 8 % increase in companion animal diagnostics, alongside growth in osteoarthritis therapies such as Lenivia® and Portela™. These gains were explicitly linked to the company’s expanding diagnostics offerings.

The company also confirmed the completion of its acquisition of VitalRADS, which expands Zoetis’s Global Diagnostics portfolio to include veterinary teleradiology services, enabling 24/7 specialist imaging support via a cloud-based platform.

Closing of VitalRADS Acquisition Adds AI and Imaging Capabilities

Zoetis originally announced the definitive agreement to acquire VitalRADS on July 14, 2026. VitalRADS offers teleradiology, mobile ultrasound, outpatient imaging, and a cloud-hosted PACS system, serving more than 1,800 veterinary customers. The acquisition is positioned to deepen Zoetis’s Virtual Reference Laboratory model by adding AI-assisted workflow, quality assurance tools, and real-time radiology interpretation across multiple imaging modalities.

Financial terms were not disclosed, but the acquisition was completed in July, reinforcing Zoetis’s strategic push into integrated diagnostics solutions.

Strategic Implications for Zoetis

The VitalRADS integration marks a meaningful enhancement to Zoetis’s diagnostic capabilities, extending its reach beyond traditional in-clinic and laboratory testing toward sophisticated imaging services—crucial amid evolving veterinary demand for rapid, comprehensive diagnostic insights.

This move aligns with Zoetis’s stated commitment to innovation and diversification, particularly as the company navigates softer demand in certain companion animal markets and increased pricing pressures.

Investor Considerations

Zoetis shares are currently trading at $73.67 (as of September 14, 2026), down 0.71 % on the day. Investors should monitor how the VitalRADS acquisition affects diagnostic revenue growth in upcoming quarters and whether it offsets softness in companion animal segments. Execution integration risks and synergies realization will also be key performance indicators to watch.

Looking Ahead

The company projects full-year revenue between $9.12 billion and $9.32 billion, revising both revenue and adjusted net income guidance downward compared with prior outlooks. Continued investment in diagnostics, alongside its pipeline of potential blockbusters across therapeutic areas, will be essential to driving growth and offsetting sector-specific headwinds.

With the VitalRADS acquisition now finalized and embedded into its diagnostics ecosystem, Zoetis gains a valuable platform for clinical support, efficiency, and innovation—that could play a pivotal role in shaping its growth trajectory through the remainder of 2026 and into 2027.

Sources: Zoetis’s second-quarter earnings release dated August 6 and the company’s July 14 announcement of the acquisition of VitalRADS.